$5.12
-1.9%CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$25.0M | -$29.5M | -$34.8M | -$41.0M | -$48.4M | -$57.2M | -$67.5M | -$79.7M | -$94.0M | -$111.0M |
| Maintenance CapEx | -$1.9K | -$2.2K | -$2.6K | -$3.1K | -$3.7K | -$4.3K | -$5.1K | -$6.0K | -$7.1K | -$8.4K |
| Owner Earnings | -$25.0M | -$29.5M | -$34.8M | -$41.0M | -$48.4M | -$57.2M | -$67.5M | -$79.7M | -$94.0M | -$111.0M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$23.1M | -$25.3M | -$27.6M | -$30.2M | -$33.0M | -$36.0M | -$39.4M | -$43.0M | -$47.0M | -$51.4M |
Continue your CALC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.